Dovato (Dolutegravir / Lamivudine)

Dovato is a medicine used to treat HIV. It combines two HIV medicines in one pill taken by mouth. It works by blocking two different steps the virus needs to make copies of itself.

Brand names:Dovato
Medication

What people taking Dovato (Dolutegravir / Lamivudine) report

Every report comes from a Lived member, sent anonymously.

Have you tried Dovato (Dolutegravir / Lamivudine) for HIV Infection?

NameHow it went

About Dovato (Dolutegravir / Lamivudine)

What It's For

Dovato is a prescription tablet that treats HIV-1, the most common type of HIV. Each tablet combines two antiviral medicines, dolutegravir and lamivudine, and together they make a complete treatment regimen on their own. It is approved for adults and for adolescents 12 and older who weigh at least 25 kg (about 55 pounds). It is used in two situations. Some people start it as their first HIV treatment. Others switch to it from a different regimen that is already working, meaning their viral load (the amount of HIV in the blood) is undetectable, below 50 copies per milliliter, and they have no history of treatment failing and no known resistance to either ingredient. Most HIV regimens use three drugs; Dovato is one of the few two-drug options, which some people prefer because it means fewer medicines to take over a lifetime.

How It Works

HIV infects CD4 cells, white blood cells that help the immune system fight infection, and uses them to make new copies of itself. Each ingredient in Dovato blocks a different step in that copying process. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI): it stops the virus from converting its genetic material into a form the cell can use. Dolutegravir is an integrase inhibitor: it stops the virus from inserting that genetic material into the cell's own DNA. With fewer new copies being made, the amount of virus in the blood falls, often to a level standard tests cannot detect. That gives the immune system room to recover and lowers the risk of AIDS (acquired immunodeficiency syndrome, the advanced stage of HIV) and HIV-related illness. Dovato does not cure HIV; the virus stays hidden in the body and returns if treatment stops.

Dosage & Administration

Dovato is taken as one tablet once a day, with or without food. Each tablet contains 50 mg of dolutegravir and 300 mg of lamivudine. Because it is a complete regimen, it is not combined with other HIV medicines. Taking it every day matters: steady drug levels keep the virus suppressed, and repeated missed doses can let resistant virus develop. If a dose is missed, take it as soon as you remember, but do not double the next dose. Some common products interfere with absorption. Antacids, some laxatives and other products containing magnesium or aluminum bind dolutegravir in the gut, so Dovato should be taken 2 hours before or 6 hours after them. Calcium or iron supplements, including multivitamins that contain them, can be taken at the same time as Dovato only if both are taken with food; otherwise space them the same way. A few medicines lower dolutegravir levels enough that the dose in the tablet is no longer sufficient. People taking rifampin (a tuberculosis antibiotic) or carbamazepine (a seizure and nerve-pain medicine) usually need an extra dolutegravir tablet about 12 hours after their Dovato dose.

Side Effects

Most people tolerate Dovato well. The most common side effects are headache, nausea, diarrhea, trouble sleeping, tiredness and anxiety, and in the main trials each affected only a few percent of people. Dolutegravir can raise the blood creatinine level slightly in the first weeks. This reflects how the kidneys handle creatinine rather than kidney damage, but it is useful to know when reading lab results. A small number of people have an allergic-type (hypersensitivity) reaction, usually as a rash. Contact the prescriber about any new rash. If a rash comes with fever, feeling very unwell, blisters or peeling skin, mouth sores, red eyes, or swelling of the face, lips or tongue, or with trouble breathing, stop taking Dovato and get medical help right away, because continuing it can make the reaction life-threatening. Liver injury is uncommon but has been reported, and liver tests are part of routine monitoring. Yellowing of the skin or eyes, dark or tea-colored urine, pale stools, or pain under the right ribs should be reported to the care team promptly. Rarely, medicines in lamivudine's class cause lactic acidosis, a dangerous buildup of acid in the blood, with an enlarged fatty liver.

Interactions & Warnings

Dovato carries a boxed warning, the FDA's most prominent kind, about hepatitis B. Lamivudine also acts against the hepatitis B virus, so everyone should be tested for hepatitis B before starting. In a person who has both infections, lamivudine on its own can allow drug-resistant hepatitis B to emerge, so additional hepatitis B treatment or a different HIV regimen is usually needed. Stopping Dovato can also cause a severe flare of hepatitis B, sometimes leading to liver failure. People with hepatitis B should not stop Dovato without a plan from their care team and need close monitoring for months afterward. Dovato must not be taken with dofetilide (Tikosyn), a heart rhythm medicine, because dolutegravir raises dofetilide to dangerous levels. Several medicines reduce dolutegravir's effect and should be avoided, including the seizure medicines oxcarbazepine, phenytoin and phenobarbital, and the herbal supplement St. John's wort. Dolutegravir also raises levels of metformin (a diabetes medicine) and dalfampridine (a multiple sclerosis medicine that can cause seizures at high levels), so those doses may need review. Tell the prescriber and pharmacist about every prescription, over-the-counter product and supplement. Because the two drugs come in a fixed-dose tablet that cannot be adjusted, Dovato is not recommended for people with severely reduced kidney function (creatinine clearance below 30 mL/min) or severe liver impairment. On pregnancy, an early study raised concern about neural tube defects (birth defects of the brain and spine) with dolutegravir at conception, but larger follow-up studies of more than 14,000 people found rates similar to other HIV regimens. Anyone pregnant, planning pregnancy or breastfeeding should talk through the options with their care team, since breastfeeding carries a risk of passing HIV to the baby.

What to Expect

In the main trials of people starting treatment, about 91 out of 100 taking dolutegravir with lamivudine had an undetectable viral load after a year, nearly the same as with a standard three-drug regimen. Those trials included only people whose starting viral load was 500,000 copies per milliliter or lower and who did not have hepatitis B or known resistance, which is why clinicians check viral load, hepatitis B status and resistance test results before choosing it. People switching from a three- or four-drug regimen generally stay suppressed on Dovato, which in one trial held for three years. Regular blood tests track viral load, CD4 count, kidney and liver function. Keeping the virus suppressed protects long-term health and lowers the chance of passing HIV to others. In the first weeks after starting HIV treatment, a recovering immune system can sometimes react to an infection that was already present but hidden, causing new or worsening symptoms; report any signs of infection promptly. HIV treatment is lifelong. Stopping lets the virus rebound and may allow resistance to develop, so any change should be planned with the care team.

Questions to Ask Your Doctor

  1. 1.Is a two-drug regimen like Dovato a good fit for me, or would a three-drug regimen be safer given my viral load and resistance test results?
  2. 2.What did my hepatitis B test show, and what would that mean for taking or stopping Dovato?
  3. 3.Do any of my current medicines, antacids or supplements need to be timed differently or changed?
  4. 4.How often will my viral load, kidney and liver tests be checked, and what results would make us change treatment?
  5. 5.If I become pregnant or plan to, would you recommend staying on Dovato?

Last reviewed • Oct 2026

Educational content, not medical advice.